The safety of pain relievers like Celebrex and Vioxx is under scrutiny due to potential heart risks.
Concerns were raised by key researchers, European regulators, and a congressman.
Studies suggest these drugs may block a substance that prevents heart problems.
The FDA's handling of Vioxx's withdrawal and safety issues has been criticized.
Merck's decision to withdraw Vioxx highlights flaws in drug safety monitoring.
The FDA's reliance on drug companies for safety oversight is questioned.
The need for more thorough, ongoing testing of approved drugs is emphasized.
Vioxx's withdrawal prompts reevaluation of drug approval processes and monitoring protocols.
